Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection
8.12.2025 05:37:00 EET | Business Wire | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/
Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally.
AI Fairness enhances Financial Security
Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities.
The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI conferences, challenged participants to develop AI models that not only achieve high-utility performance but also demonstrate fairness across demographic subgroups such as gender, age, and skin tone. Ant International emerged first among over 2,100 submissions from 162 teams across the world at the competition. These teams were tasked to detect 1.2 million AI-generated face pictures of humans from different demographic groups.
By combining a Mixture of Experts (MoE) architecture with an internal "bias-detection" mechanism, Ant International's winning AI model trains competing neural sub-networks – one focused on spotting deepfakes, the other actively challenging it to ignore sensitive traits. This dynamic ensures the system learns to detect only genuine signs of manipulation, not demographic patterns. Trained on globally representative data including real-world payment fraud scenarios, the model delivers robust and equitable performance at scale.
“A biased AI is an insecure AI,” said Dr. Tianyi Zhang, General Manager of Risk Management and Cybersecurity at Ant International. “Our model’s fairness prevents exploitation from deepfakes and ensures reliable identity verification for all users, supporting our mission to deliver secure and inclusive financial services worldwide.”
Applications in Financial Services
Ant International is integrating the NeurIPS-winning technology directly into its payment and financial services to counter deepfake threats and ensure consistent customer experience globally.
- Account protection against deepfake attacks: Ant International’s AI-powered anti-deepfake measures have achieved a detection rate exceeding 99.8%. By prioritising fairness, this ensures robust and consistent protection against sophisticated threats like account takeovers for all demographics across 200 markets worldwide.
- Enhanced compliance for eKYC processes: The company, as well as its financial institution and merchant partners, can leverage the technology to meet stringent global Electronic Know Your Customer (eKYC) standards in customer onboarding across different markets, without introducing algorithmic bias.
- Advancing financial inclusion in emerging markets: The development of equitable and accurate AI helps ensure that Ant International can extend services to a broader, more diverse market globally, fostering greater financial inclusion.
Full-cycle security strategy to protect financial transactions
Ant International alongside its partners serve over 150 million merchants and 1.8 billion user accounts worldwide. These services include global wallet gateway Alipay+, merchant payment services Antom, inclusive finance and credit tech services Bettr and global account services WorldFirst.
Ant International has positioned AI security at the core of its operations. It has introduced the AI SHIELD, as a comprehensive, full-lifecycle foundational framework for risk management. Built on the AI Security Docker, this solution reduces risk of AI service vulnerabilities such as unauthorised access and data leakage by 90% through advanced assessment methods and running safeguards.
Risk-management solutions secured by AI SHIELD provide full-lifecycle protection of transactions at Ant International. These solutions protect businesses and users from deepfake attacks, frauds and scams. For instance, account protection solution Alipay+ EasySafePay 360 can reduce account takeover incidence for digital wallet payments by 90%.
About Ant International
With headquarters in Singapore and main operations across Asia, Europe, the Middle East and Latin America, Ant International is a leading global digital payment, digitisation and financial technology provider. Through collaboration across the private and public sectors, our unified techfin platform supports financial institutions and merchants of all sizes to achieve inclusive growth through a comprehensive range of cutting-edge digital payment and financial services solutions. To learn more, please visit https://www.ant-intl.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20251207210856/en/
Contacts
For media enquiries, please contact
Ant International Global Communications
pr@ant-intl.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom